Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) saw a large growth in short interest in October. As of October 13th, there was short interest totalling 3,183,085 shares, a growth of 53.3% from the September 29th total of 2,076,679 shares. Based on an average trading volume of 2,062,293 shares, the days-to-cover ratio is presently 1.5 days. Currently, 13.8% of the shares of the company are short sold.
Shares of Marinus Pharmaceuticals (NASDAQ MRNS) opened at 5.54 on Wednesday. The stock’s market capitalization is $144.46 million. Marinus Pharmaceuticals has a one year low of $0.82 and a one year high of $8.22. The firm’s 50-day moving average is $5.39 and its 200-day moving average is $2.70.
Marinus Pharmaceuticals (NASDAQ:MRNS) last announced its earnings results on Tuesday, August 1st. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.27) by $0.06. Equities research analysts forecast that Marinus Pharmaceuticals will post ($0.74) EPS for the current year.
A hedge fund recently raised its stake in Marinus Pharmaceuticals stock. KCG Holdings Inc. lifted its holdings in shares of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) by 29.5% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 64,539 shares of the biopharmaceutical company’s stock after buying an additional 14,692 shares during the quarter. KCG Holdings Inc. owned approximately 0.30% of Marinus Pharmaceuticals worth $114,000 as of its most recent SEC filing. Institutional investors own 23.60% of the company’s stock.
Several equities research analysts recently issued reports on the stock. ValuEngine raised shares of Marinus Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, August 11th. JMP Securities reaffirmed an “outperform” rating and set a $11.00 price objective (up from $5.00) on shares of Marinus Pharmaceuticals in a report on Tuesday, September 12th.
ILLEGAL ACTIVITY NOTICE: “Marinus Pharmaceuticals, Inc. (MRNS) Sees Significant Increase in Short Interest” was originally reported by Community Financial News and is owned by of Community Financial News. If you are accessing this article on another site, it was stolen and republished in violation of US and international trademark & copyright laws. The original version of this article can be read at https://www.com-unik.info/2017/11/01/marinus-pharmaceuticals-inc-mrns-sees-significant-increase-in-short-interest.html.
About Marinus Pharmaceuticals
Marinus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings.
What are top analysts saying about Marinus Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Marinus Pharmaceuticals Inc. and related companies.